Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2009
10/29/2009US20090270515 Active ingredient containing stabilised solid medicinal forms and method for the production thereof
10/29/2009US20090270464 Benzimidazole derivative and use as a II receptor antagonist
10/29/2009US20090270455 Therapeutic agent for intestinal diseases and visceral pain
10/29/2009US20090270341 Product comprising a transduction inhibitor of heterotrimeric g protein signals combined with another anti-cancer agent for therapeutic use in the treatment of cancer
10/29/2009US20090270310 Process for the preparation of a nutrient formulation
10/29/2009US20090269739 Kit for detection of telomerase reverse transcriptase nucleic acids
10/29/2009US20090269414 Process of preparing microspheres for sustained release having improved dispersibility and syringeability
10/29/2009US20090269404 Crosslinked Gelatin Gel, Multilayered Structure, Carrier for Bioactive Factor, Preparation for Release of Bioactive Factor, and Their Production Methods
10/29/2009US20090269389 ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery
10/29/2009US20090269383 Medical devices having inorganic particle layers
10/29/2009US20090269368 Pseudomonas exotoxin a-like chimeric immunogens
10/29/2009US20090269352 Antitumor agent comprising sulfonamide-containing heterocyclic compound combined with an angiogenesis inhibitor
10/29/2009US20090269337 Compositions and methods for treating diabetes
10/29/2009US20090269316 Methods for Using a Three-Dimensional Stromal Tissue to Promote Angiogenesis
10/29/2009US20090269311 Method for treating multiple system atrophy
10/29/2009US20090269285 Diagnostic And Therapeutic Epitope, And Transgenic Plant
10/29/2009CA2753532A1 Nicotinamide derivatives
10/29/2009CA2722075A1 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient
10/29/2009CA2722041A1 Novel five-membered ring compound
10/29/2009CA2722031A1 Iminopyridine derivative and use thereof
10/29/2009CA2722028A1 5-hydroxypyrimidine-4-carboxamide compound
10/29/2009CA2722007A1 Five-membered ring compound
10/29/2009CA2721716A1 Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
10/29/2009CA2721576A1 Compound having npy y5 receptor antagonist activity
10/28/2009EP2112234A2 Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
10/28/2009EP2112219A1 Novel lactic acid bacteria
10/28/2009EP2112170A1 Cellulose derivative and method for production thereof
10/28/2009EP2112167A2 Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
10/28/2009EP2112154A1 Esters in position 20 of camptothecins
10/28/2009EP2112140A1 Chinazolin derivatives, medicine containing these compounds, application thereof and method for their production
10/28/2009EP2111870A1 Dosages for treatment of anti-erbB2 antibodies
10/28/2009EP2111862A1 Pharmaceutical product for prevention and treatment of alzheimer's dementia
10/28/2009EP2111860A1 Inflammation inhibitor comprising zinc salt of acylamino acid
10/28/2009EP1503800B1 Treatment and prevention of tissue damage associated with increased c-reactive protein production
10/28/2009EP1501538B1 Use of alpha-s2 casein precursor-derived peptides
10/28/2009EP1497438B1 Means and methods for the production of adenovirus vectors
10/28/2009EP1404323B1 Use of methylnaltrexone to treat immune suppression
10/28/2009EP1371640B1 Novel a-lipoic acid derivative and use thereof
10/28/2009EP1371377B1 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
10/28/2009EP1272168B2 Small organic molecule regulators of cell proliferation
10/28/2009EP1150666B1 Gm-csf for the treatment of crohn's disease
10/28/2009EP1098908B1 Anti-ccr2 antibodies and methods of use therefor
10/28/2009EP0975340B2 Therapeutic inhibitor of vascular smooth muscle cells
10/28/2009EP0915706B1 Screening methods for compounds useful in the regulation of body weight
10/28/2009CN101568334A Iron metabolism-improving agent
10/28/2009CN101565429A Inhibitors of dipeptidylpeptidase iv
10/28/2009CN101565412A Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
10/28/2009CN101565394A Crystalline forms of atorvastatin
10/28/2009CN101564526A Channel and collateral dredging king
10/28/2009CN101564506A Medicament for treating pyrogenic heatstroke
10/28/2009CN101564443A Chinese medicament for treating intravenous injection extravasation bruising
10/28/2009CN101564428A Medicament for treating heatstroke
10/28/2009CN100554268C Multicyclic compounds and the use as inhibitors of PARP, VEGFR2 and MLK3 enzymes
10/28/2009CN100554267C Muscle relaxation accelerator and therapeutic agent for muscular tissue diseases such as muscle relaxation failure
10/28/2009CN100554247C Muscarinic agonists
10/28/2009CN100553677C Drugs for treating vascular diseases
10/28/2009CN100553648C Chinese-medicinal composition, its preparation and uses in pharmacy
10/28/2009CN100553636C Method of using diketopiperazines and composition containing them
10/28/2009CN100553631C Pharmaceutical uses of 4-fluoro-N-(1,2- hydrindenl-2-yl) benzamide
10/27/2009US7608718 4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
10/27/2009US7608716 Pyrazolonaphthyridine derivative
10/27/2009US7608701 Corticotropin releasing factor 2 receptor agonists
10/27/2009US7608683 Human leukocyte antigen pan DR-binding peptides for use in the treatment of infections, inflammatory, autoimmune and cancer diseases; has heat shock protein that is capable of binding to MHC class II molecules
10/27/2009US7608681 Methods and compositions for prolonging elimination half-times of bioactive compounds
10/27/2009US7608634 Substituted pyrrolines as kinase inhibitors
10/27/2009US7608625 Method for treating bruxism and bruxism-related diseases
10/27/2009US7608624 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives
10/27/2009US7608618 1-(2,2,2-trifluoroethanoyl)pyrrolidine-2-carboxylic acid [4-methoxy-3-(3-pyrazin-2-yl-ureido)phenyl]-amide; 4-Methoxy-N-(3-methylamino-propyl)-3-(3-pyrazin-2-yl-ureido)-benzamide; checkpoint kinase Chk1 inhibitor; chemosensitizing agents useful in the treatment of diseases related to DNA damage
10/27/2009US7608577 Peptidyl ketones as inhibitors of DPIV
10/27/2009US7608452 Polynucleotides encoding cytokine receptor zcytor19
10/27/2009US7608411 Prostaglandin receptor EP1
10/27/2009US7608401 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis
10/27/2009US7608284 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli
10/27/2009US7608281 Retinoic acid receptors (RAR); tissue engineering, cartilage formation; for treatment of cartilage degenerative disease, skeletal trauma; bone morphogenetic protein (BMP), osteogenic protein (OP)
10/27/2009US7608269 Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
10/27/2009US7608255 Replication-competent anti-cancer vectors
10/27/2009US7608253 end-capped polyethylene glycol carbamate derivatives useful as water-soluble pro-drugs; controll hydrolytic degradation of hydrogels; conjugate polymer drug for controlled release
10/27/2009CA2477019C Use of total coumarins of cnidium fruit in preparing medicaments for treating psoriasis
10/27/2009CA2471565C Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
10/27/2009CA2466724C Benzamide and heteroarylamide as p2x7 receptor antagonists
10/27/2009CA2454664C Cancer treatment with go6976 and its related compounds
10/27/2009CA2446435C 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
10/27/2009CA2437006C Aminotriazolopyridine derivatives as adenosine receptor ligands
10/27/2009CA2435426C Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof
10/27/2009CA2432713C Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
10/27/2009CA2421826C Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
10/27/2009CA2381885C Isomeric fused pyrrolocarbazoles and isoindolones
10/27/2009CA2381165C Novel quinuclidine derivatives and medicinal compositions containing the same
10/27/2009CA2376355C N-heterocyclic derivatives as nos inhibitors
10/27/2009CA2363792C Percutaneous absorption preparation of compound having angiotensin ii antagonistic activity
10/27/2009CA2349529C Pge synthase and methods and means for modulating its activity
10/27/2009CA2319837C Hydroxylation activated drug release
10/27/2009CA2318145C Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
10/22/2009WO2009128918A1 Combination therapy using a soluble hyaluronidase and a bisphosphonate
10/22/2009WO2009128558A1 Activator for peroxisome proliferator-activated receptor
10/22/2009WO2009128547A1 Gene expression inhibitor selective for matrix metalloproteinase-9 gene
10/22/2009WO2009128537A1 Heterocyclic compound
10/22/2009WO2009128521A1 Cysteine protease inhibitor
10/22/2009WO2009128520A1 Heterocyclic compound having inhibitory activity on p13k
10/22/2009WO2009128481A1 Nitrogenated 5-membered heterocyclic compound
1 ... 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 ... 1564